Who are Colchicine (for 1 month)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel (Pac), Docetaxel (D), Standard of Care: Docetaxel, VLI, VIN, albendazole and praziquantel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/colchicine-for-1-month.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Colchicine (for 1 month) — Competitive Intelligence Brief

Colchicine (for 1 month) (Colchicine (for 1 month)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor / Anti-inflammatory agent. Area: Immunology / Rheumatology / Cardiovascular.

phase 3 Microtubule inhibitor / Anti-inflammatory agent β-tubulin Immunology / Rheumatology / Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Colchicine (for 1 month) (Colchicine (for 1 month)) — Azienda Sanitaria Locale 3, Torino. Colchicine inhibits microtubule polymerization by binding to tubulin, thereby suppressing inflammatory cell migration and reducing production of inflammatory mediators.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Colchicine (for 1 month) TARGET	Colchicine (for 1 month)	Azienda Sanitaria Locale 3, Torino	phase 3	Microtubule inhibitor / Anti-inflammatory agent	β-tubulin
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Docetaxel (D)	Docetaxel (D)	BeyondSpring Pharmaceuticals Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin
Standard of Care: Docetaxel	Standard of Care: Docetaxel	H. Lee Moffitt Cancer Center and Research Institute	marketed	Taxane; microtubule stabilizer	β-tubulin
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin
VIN	VIN	Italian Sarcoma Group	marketed	Vinca alkaloid; microtubule inhibitor	β-tubulin
albendazole and praziquantel	albendazole and praziquantel	R-Evolution Worldwide S.r.l. Impresa Sociale	marketed	Anthelmintic combination	β-tubulin (albendazole); calcium channels (praziquantel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule inhibitor / Anti-inflammatory agent class)

Azienda Sanitaria Locale 3, Torino · 3 drugs in this class
Brigham and Women's Hospital · 1 drug in this class
The George Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Colchicine (for 1 month) — Competitive Intelligence Brief. https://druglandscape.com/ci/colchicine-for-1-month. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab